unknown by unknown
Reply to the Editor:
We thank Professor Matsubara for his kind comments
regarding our article and respectfully acknowledge his
numerous contributions to the field. He quite correctly
points out that the number of patients in our series was
small; however, in our updated experience of nearly 50
patients the data still hold. Approximately 40% of patients
with tumors in the middle third of the thoracic esophagus
(mostly squamous cancers) have metastasis to the cervi-
cothoracic regions, specifically the recurrent nerve nodes,
and approximately 25% to 30% of patients with tumors in
the lower third of the esophagus (mostly adenocarcino-
mas) have metastases to that region. We agree with
Professor Matsubara that comparisons between lung and
esophageal cancers are probably not warranted because
these anatomic neighbors have patently different pathways
of lymphatic drainage.
We also find that metastasis to the azygos nodes and the
nodes in front of the trachea are an uncommon occur-
rence in esophageal cancer. Finally, we believe that al-
though randomized trials have become the gold standard
for reaching definitive conclusions regarding therapeutic
interventions, they are by no means the only way of
assessing the efficacy of an intervention. Data that are
prospectively acquired and carefully documented and
controlled form the basis of time-honored observational
studies that have advanced the cause of medicine over the
years. It would seem unlikely in our opinion that a
randomized trial comparing three-field dissection (or a
radical two-field dissection) to lesser resections would
result in any meaningful results, primarily because of the
understaging of the disease that is an inherent defect in all
limited resections.
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